SAR-096: Phase II clinical trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).
Sujana MovvaSahar MatloobElizabeth A HandorfEdwin ChoyPriscilla MerriamDouglas B FliederKathy Q CaiYan ZhouEric D TetzlaffCheyenne PaganEmma BarkerRosanna VeggebergDelia ZumpanoLori RinkMargaret von MehrenSuzanne GeorgePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The combination of ribociclib and everolimus demonstrates activity in DDL with prolonged stable disease (≥16 weeks) meeting the primary endpoint. Notably partial responses were observed. The primary endpoint was not reached in the LMS cohort. The combination was well tolerated with expected side effects.